JP2008510762A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008510762A5 JP2008510762A5 JP2007528748A JP2007528748A JP2008510762A5 JP 2008510762 A5 JP2008510762 A5 JP 2008510762A5 JP 2007528748 A JP2007528748 A JP 2007528748A JP 2007528748 A JP2007528748 A JP 2007528748A JP 2008510762 A5 JP2008510762 A5 JP 2008510762A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- following
- nhch
- following group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- XHIGERJLTCYABW-UHFFFAOYSA-N 3-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]cyclohexane-1-carboxylic acid Chemical compound CC(C)(C)OC(=O)NCC1CCCC(C(O)=O)C1 XHIGERJLTCYABW-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- -1 6-methoxy- [1,5] -naphthyridin -4-yl Chemical group 0.000 description 1
- XAJVMBAGZCPRJF-UHFFFAOYSA-N CC(C)(C)c(cc(c(SC1)c2)NC1=O)c2F Chemical compound CC(C)(C)c(cc(c(SC1)c2)NC1=O)c2F XAJVMBAGZCPRJF-UHFFFAOYSA-N 0.000 description 1
- KVNUWVOKXOWLDA-UHFFFAOYSA-N Cc(cc1)nc(N2)c1SCC2=O Chemical compound Cc(cc1)nc(N2)c1SCC2=O KVNUWVOKXOWLDA-UHFFFAOYSA-N 0.000 description 1
- JSBZPNRRLJLZBE-UHFFFAOYSA-N Cc(cc1N2)ccc1OCC2=O Chemical compound Cc(cc1N2)ccc1OCC2=O JSBZPNRRLJLZBE-UHFFFAOYSA-N 0.000 description 1
- RPZKLNMJEGXWTO-UHFFFAOYSA-N Cc(cc1N2)ccc1SC/C2=[O]\C[I]=C Chemical compound Cc(cc1N2)ccc1SC/C2=[O]\C[I]=C RPZKLNMJEGXWTO-UHFFFAOYSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N anhydrous n-heptane Natural products CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004041163A DE102004041163A1 (de) | 2004-08-25 | 2004-08-25 | Neue Verbindungen mit antibakterieller Aktivität |
| PCT/EP2005/009204 WO2006021448A1 (en) | 2004-08-25 | 2005-08-25 | Novel compounds having an anti-bacterial activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008510762A JP2008510762A (ja) | 2008-04-10 |
| JP2008510762A5 true JP2008510762A5 (enExample) | 2008-10-16 |
Family
ID=35431960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007528748A Withdrawn JP2008510762A (ja) | 2004-08-25 | 2005-08-25 | 抗菌活性を有する新規な化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20070244103A1 (enExample) |
| EP (1) | EP1781650A1 (enExample) |
| JP (1) | JP2008510762A (enExample) |
| KR (1) | KR20070045152A (enExample) |
| CN (1) | CN101035785A (enExample) |
| AU (1) | AU2005276576A1 (enExample) |
| BR (1) | BRPI0514665A2 (enExample) |
| CA (1) | CA2571132A1 (enExample) |
| DE (1) | DE102004041163A1 (enExample) |
| IL (1) | IL179837A0 (enExample) |
| MX (1) | MX2007002097A (enExample) |
| NZ (1) | NZ552036A (enExample) |
| RU (1) | RU2410386C2 (enExample) |
| WO (1) | WO2006021448A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1796466A4 (en) | 2004-06-15 | 2009-09-02 | Glaxo Group Ltd | ANTIBACTERIAL AGENTS |
| JP4887297B2 (ja) * | 2004-09-24 | 2012-02-29 | アクテリオン ファーマシューティカルズ リミテッド | 新規二環式抗生物質 |
| MY150958A (en) | 2005-06-16 | 2014-03-31 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
| WO2007042325A1 (de) * | 2005-10-13 | 2007-04-19 | Morphochem Aktiengesellschaft für kombinatorische Chemie | 5-chinolinderivate mit antibakterieller aktivität |
| US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| ATE481406T1 (de) | 2006-04-06 | 2010-10-15 | Glaxo Group Ltd | Pyrrolochinoxalinonderivate als antibakterielle mittel |
| GB0608263D0 (en) * | 2006-04-26 | 2006-06-07 | Glaxo Group Ltd | Compounds |
| GB0613208D0 (en) | 2006-07-03 | 2006-08-09 | Glaxo Group Ltd | Compounds |
| EP1992628A1 (en) | 2007-05-18 | 2008-11-19 | Glaxo Group Limited | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones |
| TW200819457A (en) | 2006-08-30 | 2008-05-01 | Actelion Pharmaceuticals Ltd | Spiro antibiotic derivatives |
| CL2007003693A1 (es) | 2006-12-22 | 2008-06-27 | Actelion Pharmaceuticals Ltd | Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas. |
| CL2008001003A1 (es) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
| PT2137196E (pt) * | 2007-04-20 | 2010-12-16 | Glaxo Group Ltd | Compostos tricíclicos contendo azoto como agentes antibacterianos |
| US8759348B2 (en) * | 2007-05-17 | 2014-06-24 | Helperby Therapeutics Limited | Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms |
| CA2689102C (en) * | 2007-06-15 | 2016-07-26 | Actelion Pharmaceuticals Ltd | 3-amino-6-(1-amino-ethyl)-tetrahydropyran derivatives |
| JP5323088B2 (ja) | 2007-12-18 | 2013-10-23 | アクテリオン ファーマシューティカルズ リミテッド | ５−アミノシクリルメチル−オキサゾリジン−２−オン誘導体 |
| EP2080761A1 (en) | 2008-01-18 | 2009-07-22 | Glaxo Group Limited | Compounds |
| WO2009097578A1 (en) | 2008-02-01 | 2009-08-06 | Takeda Pharmaceutical Company Limited | Oxim derivatives as hsp90 inhibitors |
| BRPI0907892A2 (pt) | 2008-02-20 | 2015-07-28 | Actelion Pharmaceuticals Ltd | Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo |
| WO2009128019A1 (en) | 2008-04-15 | 2009-10-22 | Actelion Pharmaceuticals Ltd | Tricyclic antibiotics |
| JP4833385B1 (ja) | 2008-10-07 | 2011-12-07 | アクテリオン ファーマシューティカルズ リミテッド | 三環式オキサゾリジノン抗生物質化合物 |
| JP2012505866A (ja) | 2008-10-17 | 2012-03-08 | グラクソ グループ リミテッド | 抗菌剤として使用される三環式窒素化合物 |
| US8318940B2 (en) | 2009-01-15 | 2012-11-27 | Glaxo Group Limited | Naphthyridin-2 (1 H)-one compounds useful as antibacterials |
| US8716280B2 (en) | 2009-01-21 | 2014-05-06 | Basilea Pharmaceutica Ag | Bicyclic antibiotics |
| EP2332939A1 (en) | 2009-11-26 | 2011-06-15 | Æterna Zentaris GmbH | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors |
| JP5697685B2 (ja) | 2009-12-18 | 2015-04-08 | バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ | 三環式抗生物質 |
| CN103635474B (zh) | 2011-06-17 | 2016-04-27 | 巴斯利尔药物股份公司 | 三环抗生素 |
| TW201326180A (zh) | 2011-11-30 | 2013-07-01 | Actelion Pharmaceuticals Ltd | ３，７－二取代八氫－２Ｈ－吡啶并［４，３－ｅ］［１，３］□嗪－２－酮抗生素 |
| AR090844A1 (es) * | 2012-04-27 | 2014-12-10 | Actelion Pharmaceuticals Ltd | Proceso para elaborar derivados de naftiridina |
| CN104803913B (zh) * | 2014-01-24 | 2019-02-12 | 浙江省化工研究院有限公司 | 一种碳酸苄基喹啉基酯类化合物、其制备方法及应用 |
| AR101674A1 (es) | 2014-08-22 | 2017-01-04 | Glaxosmithkline Ip Dev Ltd | Uso de un compuesto tricíclico que contiene nitrógeno |
| MA41169A (fr) | 2014-12-17 | 2017-10-24 | Acraf | Composés antibactériens à large spectre d'activité |
| MA41168A (fr) | 2014-12-17 | 2017-10-24 | Acraf | Nouveaux composés antibactériens |
| UY36851A (es) | 2015-08-16 | 2017-03-31 | Glaxosmithkline Ip Dev Ltd | Compuestos para uso en aplicaciones antibacterianas |
| EP3468975B1 (en) | 2016-06-08 | 2020-04-01 | Aziende Chimiche Riunite Angelini Francesco A.C.R. | New antibacterial compounds |
| AR111295A1 (es) | 2017-03-20 | 2019-06-26 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| MX2022003025A (es) | 2019-09-19 | 2022-04-07 | Forma Therapeutics Inc | Activacion de la piruvato cinasa r. |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| IL299612A (en) | 2020-07-02 | 2023-03-01 | Incyte Corp | Tricyclic urea compounds as JAK2 V617F inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| CA3211748A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| SMT202500447T1 (it) | 2021-11-02 | 2026-01-12 | Flare Therapeutics Inc | Agonisti inversi di pparg e loro usi |
| IL315647A (en) | 2022-03-17 | 2024-11-01 | Incyte Corp | Tricyclic urea compounds as Jak2 and 617f inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2140417C1 (ru) * | 1995-10-17 | 1999-10-27 | Институт физиологически активных веществ РАН | Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения |
| GB0112834D0 (en) * | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| JP4445753B2 (ja) * | 2002-01-29 | 2010-04-07 | グラクソ グループ リミテッド | アミノピペリジン誘導体 |
| AR040335A1 (es) * | 2002-06-26 | 2005-03-30 | Glaxo Group Ltd | Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto |
| DE10256405A1 (de) * | 2002-12-02 | 2004-06-17 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen, die Topoisomerase IV inhibieren |
| DE10247233A1 (de) * | 2002-10-10 | 2004-06-17 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen, die Topoisomerase IV inhibieren |
| JP4602903B2 (ja) * | 2002-10-10 | 2010-12-22 | モルフォケム アクチェンゲゼルシャフト フュア コンビナトリシェ ヘミー | 抗菌活性を有する新規化合物 |
| AR042486A1 (es) * | 2002-12-18 | 2005-06-22 | Glaxo Group Ltd | Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion . |
-
2004
- 2004-08-25 DE DE102004041163A patent/DE102004041163A1/de not_active Withdrawn
-
2005
- 2005-08-25 CA CA002571132A patent/CA2571132A1/en not_active Abandoned
- 2005-08-25 KR KR1020067026765A patent/KR20070045152A/ko not_active Ceased
- 2005-08-25 EP EP05787944A patent/EP1781650A1/en not_active Withdrawn
- 2005-08-25 JP JP2007528748A patent/JP2008510762A/ja not_active Withdrawn
- 2005-08-25 RU RU2007105995/04A patent/RU2410386C2/ru not_active IP Right Cessation
- 2005-08-25 AU AU2005276576A patent/AU2005276576A1/en not_active Abandoned
- 2005-08-25 CN CNA200580028501XA patent/CN101035785A/zh active Pending
- 2005-08-25 BR BRPI0514665-8A patent/BRPI0514665A2/pt not_active IP Right Cessation
- 2005-08-25 US US11/660,894 patent/US20070244103A1/en not_active Abandoned
- 2005-08-25 MX MX2007002097A patent/MX2007002097A/es not_active Application Discontinuation
- 2005-08-25 WO PCT/EP2005/009204 patent/WO2006021448A1/en not_active Ceased
- 2005-08-25 NZ NZ552036A patent/NZ552036A/en not_active IP Right Cessation
-
2006
- 2006-12-05 IL IL179837A patent/IL179837A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7536721B2 (ja) | キナーゼを修飾する１ｈ－ピロロ［２，３－ｂ］ピリジン誘導体の合成 | |
| JP2007515432A5 (enExample) | ||
| JP2022031717A5 (enExample) | ||
| JP2008517915A5 (enExample) | ||
| JP2013539765A5 (enExample) | ||
| JP2012510524A5 (enExample) | ||
| JP2010540593A5 (enExample) | ||
| JP2007530598A5 (enExample) | ||
| Han et al. | A convergent route to substituted azetidines and to Boc-protected 4-aminomethylpyrroles | |
| EA200802385A1 (ru) | КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 11β-(4-АЦЕТИЛФЕНИЛ)-20,20,21,21,21-ПЕНТАФТОР-17-ГИДРОКСИ-19-НОР-17A-ПРЕГНА-4,9-ДИЕН-3-ОНА | |
| JP6204223B2 (ja) | チオピラノース化合物等の製造方法 | |
| JP3771566B2 (ja) | １−オキサセファロスポリン−７α−メトキシ−３−クロルメチル誘導体の製法 | |
| JP2008203641A (ja) | シンナモイル基を持つジアミン化合物の製造法 | |
| JP2008509896A (ja) | 保護化アミノチアゾールのフッ素化方法 | |
| JP2006522034A5 (enExample) | ||
| JP2009143931A (ja) | テトラゾリルベンゾピランの製法 | |
| JP2005510568A5 (enExample) | ||
| JP4559385B2 (ja) | プランルカストまたはその水和物の製造方法、及びその合成中間体 | |
| CN103755664B (zh) | 4-芳基噻（硒）唑类化合物及其用途 | |
| US20070173648A1 (en) | Method for preparing n-aminopiperidine and its salts | |
| BRPI0714705A2 (pt) | derivado de 3'-etinilcitidina | |
| JP7323876B2 (ja) | クロピドグレル硫酸塩のｉ型結晶の製造方法 | |
| JP2024525792A5 (enExample) | ||
| CN101918416A (zh) | 制备取代的1,3-氧硫杂环戊烷,尤其是拉米夫定的方法和中间体 | |
| TW202241907A (zh) | 製備shp2抑制劑之方法 |